The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric patients three years and older with acute ...

The FDA expanded the approval of the direct-acting antiviral (DAA) glecaprevir/pibrentasvir (Mavyret), making it the first ...

Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.

Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.

Shares of AbbVie (ABBV) traded over 1% higher on Wednesday after the company announced that the U.S. Food and Drug ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

Hepatitis C virus (HCV) infection is highly associated with the development of metabolic dysfunction-associated steatotic ...

This article provides a comprehensive look at how healthcare settings can prevent the transmission of bloodborne pathogens ...

The HIV/HBV/HCV test kits market plays a vital role in the global fight against infectious diseases. These diagnostic tools are crucial for early detection and effective treatment of HIV, hepatitis B ...

aDepartment of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan bDepartment of Internal Medicine, National Taiwan University ...

Some forms of the virus can become chronic and lead to life-threatening complications. Other symptoms resolve without any specific treatment. The most common types of hepatitis are HAV and HCV. HAV is ...